Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Rabeprazole Sodium). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Prinix 20 এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Dosage Active Duodenal Ulcer and Active Benign Gastric Ulcer: For both active duodenal ulcer and active benign gastric ulcer, the recommended oral dose is 20 mg taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks, though a few may need an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks, though again a few may need an additional six weeks of therapy to achieve healing. Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg taken once daily for four to eight weeks. Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending on patient response. Symptomatic Treatment of Moderate to Very Severe Gastro-Esophageal Reflux Disease (Symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved within four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on demand regimen, taking 10 mg once daily as needed. Treatment of GERD in Pediatric Patients 1 to 11 Years of Age (Less than 15 kg): 5 mg once daily for 12 weeks, with the option to increase to 10 mg if the response is inadequate. Treatment of GERD in Pediatric Patients 1 to 11 Years of Age (15 kg or More): 10 mg once daily for 12 weeks. Zollinger Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg per day based on individual patient needs. Single daily doses up to 100 mg per day may be given. A 120 mg dose may require divided dosing, given as 60 mg twice daily. Treatment should continue for as long as clinically indicated. Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended: rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily.
পার্শ্বপ্রতিক্রিয়া
Rabsil সাধারণত স্বল্পমেয়াদী এবং দীর্ঘমেয়াদী দুই ক্ষেত্রেই ভালোভাবে সহ্য হয়। কিছু মানুষ মাথাব্যথা, ডায়রিয়া, পেটে ব্যথা, বমি, কোষ্ঠকাঠিন্য, মুখ শুকিয়ে যাওয়া, ক্ষুধায় পরিবর্তন (বেড়ে যাওয়া বা কমে যাওয়া), পেশিতে ব্যথা, ঝিমুনি বা মাথা ঘোরার মতো পার্শ্বপ্রতিক্রিয়া লক্ষ্য করতে পারেন।
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Just because symptoms improve while taking Rabsil does not rule out the presence of a cancer in the stomach or oesophagus, so this possibility should be ruled out before starting Rabsil 20 mg Gastro-resistant Tablets. Anyone on long term treatment, particularly those treated for more than 1 year, should be checked regularly by their doctor. Proton pump inhibitors, particularly at high doses and when used for more than 1 year, may modestly raise the risk of fractures of the hip, wrist and spine, mainly in elderly patients or those with other known risk factors. Observational studies suggest that proton pump inhibitors may raise the overall fracture risk by 10 to 40%, though some of this increase may stem from other risk factors. Patients at risk of osteoporosis should be monitored carefully and should get enough vitamin D and calcium. A risk of cross sensitivity reactions with other proton pump inhibitors or substituted benzimidazoles cannot be ruled out. Patients should be told that Rabsil gastro-resistant tablets must not be chewed or crushed and should be swallowed whole. There have been reports since the medicine reached the market of blood disorders such as low platelet counts (thrombocytopenia) and low neutrophil counts (neutropenia). In most cases where no other cause could be found, these events were straightforward and resolved once rabeprazole was stopped. Abnormal liver enzyme results have been seen both in clinical trials and in reports since market authorisation, and in most cases where no other cause could be found, these too were straightforward and resolved once rabeprazole was stopped. No meaningful safety concerns were seen in a study comparing patients with mild to moderate liver impairment against normal, age and sex matched controls. However, because there is no clinical data on using rabeprazole in patients with severe liver dysfunction, doctors are advised to use caution when starting treatment with Rabsil 20 mg Gastro-resistant Tablets in such patients. Taking atazanavir together with Rabsil is not recommended. Treatment with proton pump inhibitors, including rabeprazole, may possibly raise the risk of gut infections such as Salmonella, Campylobacter and Clostridium difficile. Low magnesium levels: Severe drops in blood magnesium have been reported in patients treated with PPIs such as rabeprazole for at least three months, and in most cases for about 1 year. Serious effects of low magnesium, such as fatigue, muscle spasms, confusion, seizures, dizziness and an irregular heartbeat arising from the ventricles, can occur, though they may develop gradually and go unnoticed. In most affected patients, magnesium levels improved after magnesium replacement and stopping the PPI. For patients expected to be on prolonged treatment, or who take PPIs alongside digoxin or drugs that can lower magnesium, such as diuretics, healthcare professionals should consider checking magnesium levels before starting PPI treatment and periodically afterward. Influence on vitamin B12 absorption: Like all acid blocking medicines, Rabsil may reduce the absorption of vitamin B12 (cyanocobalamin) because it lowers or removes stomach acid. This should be kept in mind for patients with low body stores of vitamin B12 or other risk factors for poor absorption who are on long term therapy, or if related symptoms appear. Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are linked to very rare cases of SCLE. If skin lesions appear, particularly on sun exposed areas, and are accompanied by joint pain, the patient should seek medical help promptly, and the healthcare professional should consider stopping Rabsil. Patients who have had SCLE after previous treatment with a proton pump inhibitor may be at higher risk of SCLE with other proton pump inhibitors. Interference with laboratory tests: A raised Chromogranin A (CgA) level may interfere with tests for neuroendocrine tumours. To avoid this, Rabsil 20 mg Gastro-resistant Tablets treatment should be stopped for at least 5 days before CgA is measured. If CgA and gastrin levels have not returned to the reference range after the first measurement, they should be measured again 14 days after stopping the proton pump inhibitor.
নিষেধাজ্ঞা
Rabeprazole sodium বা এর যেকোনো উপাদানের প্রতি অতিরিক্ত সংবেদনশীলতা। গর্ভাবস্থায় বা স্তন্যদানকালে এই ওষুধ ব্যবহার করা উচিত নয়।